FATE - Fate Therapeutics: Slowly Getting To An Attractive Position February, 21 2022 01:22 AM Fate Therapeutics Inc. Fate's ASH data has allayed concerns about durability through multiple dosing. More needs to be seen before a registrational trial can be planned. However, things aren't going too badly. For further details see: Fate Therapeutics: Slowly Getting To An Attractive Position